

(E)-1-(4-Carboxyphenylmethylene)-2-tetralone

Eliud O. Oloo,^a J. Wilson Quail,^{a*} Maniyan P. Padmanilayam^b and Jonathan R. Dimmock^b

^aDepartment of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan, Canada S7N 5C9, and ^bCollege of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan, Canada S7N 5C9

Correspondence e-mail: quail@sask.usask.ca

Key indicators

Single-crystal X-ray study

T = 193 K

Mean $\sigma(\text{C}-\text{C}) = 0.004 \text{ \AA}$

R factor = 0.059

w*R* factor = 0.154


Data-to-parameter ratio = 13.5

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The title compound, C₁₈H₁₄O₃, crystallizes in space group *P*2₁/*c* as hydrogen-bonded dimers with crystallographic inversion symmetry.

Comment

One of the major interests in this laboratory is the preparation of novel α,β -unsaturated ketones and related compounds as candidate cytotoxic and anticancer agents (Dimmock *et al.*, 1999, 2000). In a recent study, compound (*E*)-1-(4-carboxyphenylmethylene)-2-tetralone, (**I**), was prepared as a prototypic candidate cytotoxic agent by the condensation between 4-carboxybenzaldehyde and 2-tetralone. X-ray crystallography reveals that the aryl aldehyde condensed at position 1 of 2-tetralone, and the configuration of the olefinic double bond adopts *E* stereochemistry. In the bicyclic tetralone part of (**I**), atoms C2 to C9 are planar within 0.021 Å. Atoms C1 and C10 lie at distances of 0.639 and 0.959 Å, respectively, on the same side of this plane.



Compound (**I**) possesses an IC₅₀ figure of 19.3 μM against murine P388 cells and no toxicity was noted when a dose of 300 mg kg⁻¹ was administered to mice. The development of analogues of (**I**) is currently underway, with a view to producing compounds with increased cytotoxicity unaccompanied by murine toxicity.

Hydrogen bonds for compound (**I**) are shown in Table 1. (**I**) is a carboxylic acid, and its structure shows crystallographically centrosymmetric hydrogen-bonded dimers. The O...O distances are quite short at 2.64 (2) Å. Based on a normalized H-atom position (O—H = 0.84 Å), the H...O distance is 1.81 Å and the O—H...O angle is 170°. In addition, there are non-classical hydrogen bonds from C5 to O1 between molecules, linking them into chains parallel to the *c* axis.

Experimental

Compound (**I**) (m.p. 504–506 K) was prepared in 40% yield by a literature method (Jha *et al.*, 2002). The single-crystal used in the X-ray crystallographic determination was obtained from the reaction product. The evaluation using P388 cells was carried out by a

Received 10 May 2002

Accepted 14 May 2002

Online 24 May 2002




Figure 1
A general view of (I), with ellipsoids drawn at the 50% probability level.

literature procedure (Phillips *et al.*, 1989), and neurotoxicity was determined at the end of 0.5 and 4 h using a reported method (Stables & Kupferberg, 1997).

Crystal data

$C_{18}H_{14}O_3$
 $M_r = 278.29$
 Monoclinic, $P2_1/c$
 $a = 6.435$ (2) Å
 $b = 14.604$ (6) Å
 $c = 16.388$ (6) Å
 $\beta = 118.641$ (7)°
 $V = 1351.6$ (9) Å³
 $Z = 4$

$D_x = 1.368$ Mg m⁻³
 Mo $K\alpha$ radiation
 Cell parameters from 2457 reflections
 $\theta = 2.5$ – 25°
 $\mu = 0.09$ mm⁻¹
 $T = 193$ (2) K
 Fragment, yellow
 $0.35 \times 0.22 \times 0.08$ mm

Data collection

Bruker SMART CCD area-detector diffractometer
 φ and ω scans
 Absorption correction: none
 6165 measured reflections
 2571 independent reflections

1652 reflections with $I > 2\sigma(I)$
 $R_{int} = 0.078$
 $\theta_{max} = 25.9^\circ$
 $h = -7 \rightarrow 6$
 $k = 0 \rightarrow 17$
 $l = 0 \rightarrow 20$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.059$
 $wR(F^2) = 0.154$
 $S = 0.94$
 2571 reflections
 191 parameters

H-atom parameters constrained
 $w = 1/[\sigma^2(F_o^2) + (0.0842P)^2]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{max} < 0.001$
 $\Delta\rho_{max} = 0.26$ e Å⁻³
 $\Delta\rho_{min} = -0.26$ e Å⁻³

Table 1

Hydrogen-bonding geometry (Å, °).

$D-H \cdots A$	$D-H$	$H \cdots A$	$D \cdots A$	$D-H \cdots A$
$O3-H3 \cdots O2^i$	0.84	1.81	2.643 (2)	170
$C5-H5 \cdots O1^{ii}$	0.95	2.52	3.321 (3)	142
$C11-H11 \cdots O1$	0.95	2.30	2.735 (3)	107

Symmetry codes: (i) $-x, -y, -z$; (ii) $x, \frac{1}{2} - y, z - \frac{1}{2}$.

All H atoms were placed in calculated positions ($O-H = 0.84$ Å, $C-H = 0.99$ Å on aliphatic C atoms and 0.95 Å on aromatic C atoms). $U_{iso}(H)$ values were assigned as $1.2U_{eq}$ of the parent atom.

Data collection: SMART (Bruker, 1997); cell refinement: SMART; data reduction: SAINT (Bruker, 1997); program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: Xtal3.7 (Hall *et al.*, 2000); software used to prepare material for publication: SHELXL97.

Financial assistance for this project was provided by the Natural Sciences and Engineering Research Council of Canada for an operating grant to JWQ. This work was also supported by a grant to JRD from Purdue Neuroscience Co., USA. We thank Dr R. MacDonald, University of Alberta, for collecting the diffraction data. Appreciation is extended to Dr T. M. Allen, University of Alberta, Canada, and Mr J. P. Stables, National Institute of Neurological Disorders and Stroke, Bethesda, USA, who supervised the P388 and murine toxicity evaluations, respectively.

References

- Bruker (1997). SMART and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
- Dimmock, J. R., Elias, D. W., Beazely, M. A. & Kandepu, N. M. (1999). *Curr. Med. Chem.* **6**, 1125–1149.
- Dimmock, J. R., Kumar, P., Nazarali, A. J., Motaganahalli, N. L., Kowalchuk, T. P., Beazely, M. A., Quail, J. W., Oloo, E. O., Allen, T. M., Szydowski, J., DeClercq, E. & Balzarini, J. (2000). *Eur. J. Med. Chem.* **35**, 967–977.
- Hall, S. R., du Boulay, D. J. & Olthof-Hazekamp, R. (2000). Editors. *The Xtal3.7 System*. University of Western Australia, Australia.
- Jha, A., Padmanilayam, M. P. & Dimmock, J. R. (2002). *Synthesis*, pp. 463–465.
- Phillips, O. A., Nelson, L. A., Knaus, E. E., Allen, T. M. & Fathi-Afshar, F. (1989). *Drug Des. Deliv.* **4**, 121–127.
- Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
- Stables, J. P. & Kupferberg, H. J. (1997). *Molecular and Cellular Targets for Antiepileptic Drugs*, edited by G. Avanzini, P. Tanganelli and M. Avoli, pp. 191–198. London: John Libbey and Company Ltd.